Analyst Price Target is $2.25
▲ +837.50% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Quotient in the last 3 months. The average price target is $2.25, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 837.50% upside from the last price of $0.24.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in Quotient. This rating changed within the last month from a Hold consensus rating.
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ COVID-19 Microarray that is designed as a serological disease screening microarray specific to COVID-19 antibody detection. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.